Conduct HIT-to-lead progression studies on interventional agents: identification of anti-HIV lead compounds
Ended Awarded Last action
- Contract number
- 75N93023F00001
- Awardee
-
Southern Research Institute UEI CDZJAJJHJMH5
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $403,478
Award facts
- Opportunity
-
- 75N93023F00002 Solicitation number
- Contract value 100% obligated
- $403,478.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Birmingham, AL 35205, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $403,478 |
About this award
Southern Research Institute, a non-profit biomedical research organization based in Birmingham, Alabama, has received a delivery order valued at $403,478 under the National Institute of Allergy and Infectious Diseases (NIAID) "Preclinical Services for HIV Therapeutics" Indefinite Delivery/Indefinite Quantity (IDIQ) master contract. The delivery order, awarded on September 1, 2023, with an ultimate completion date of August 31, 2026, tasks Southern Research with conducting hit-to-lead progression studies on interventional agents to identify anti-HIV lead compounds. This work represents specialized preclinical drug development research aimed at advancing therapeutic candidates against HIV. The contract is structured as a cost-plus-fixed-fee arrangement with no set-aside designation, allowing Southern Research to leverage its extensive experience in infectious disease research and drug discovery to support NIAID's critical public health mission.
Southern Research's selection for this task order underscores its established role as a key federal research partner in HIV therapeutic development. The organization holds significant NIAID contracts totaling over $250 million across multiple IDIQs focused on preclinical infectious disease models and HIV therapeutics services, positioning it as a premier provider of early-stage drug development support. The hit-to-lead progression work under this delivery order will contribute to the broader federal effort to develop new treatment options for HIV, building upon Southern Research's demonstrated capabilities in compound screening, preclinical modeling, and therapeutic evaluation that have been refined through prior collaboration with NIAID and other health agencies.
Quick answers
Who was awarded contract 75N93023F00001?
75N93023F00001 was awarded to Southern Research Institute by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 1, 2023.
How much is contract 75N93023F00001 worth?
The government has obligated $403,478 on 75N93023F00001.
Is contract 75N93023F00001 an order under another contract?
Yes. 75N93023F00001 is a delivery order under 75N93021D00010, an indefinite delivery contract, on Preclinical Services for HIV Therapeutics.
Was contract 75N93023F00001 competed?
The extent of competition for 75N93023F00001 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award